Welcome to our dedicated page for GENOIL SEC filings (Ticker: GNOLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENOIL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENOIL's regulatory disclosures and financial reporting.
Genoil Inc. files its annual Form 20-F showing it remains a development-stage oil and gas technology company with no commercial revenues and significant accumulated losses of $106.6 million as of December 31, 2025. The company has incurred recurring operating losses and negative cash flows and discloses a going concern risk, while management believes ongoing access to equity financing can fund operations for the next twelve months.
Genoil had 2,018,347,429 common shares outstanding at year-end 2025, up from 1,969,322,429 in 2024, after multiple low-dollar private placements and share-based compensation. It also lists 962,881,139 potentially dilutive instruments, indicating potential dilution of 48%. Two insiders, David Lifschultz and Bruce Abbott, beneficially own about 37.54% and 22.13% of the stock, respectively, and receive no cash compensation, relying instead on equity-linked awards. The shares trade on the OTC market at very low prices, with a 2025 high of $0.02 and lows at or near zero, and the company reports a material weakness in internal controls due to inadequate segregation of duties.